Gilead Sciences Inc (GILD)

GILD (NASDAQ:Drugs) EQUITY
$78.52
neg -0.45
-0.57%
Today's Range: 78.98 - 79.34 | GILD Avg Daily Volume: 10,615,900
Last Update: 09/29/16 - 10:06 AM EDT
Volume: 573,702
YTD Performance: -21.96%
Open: $79.16
Previous Close: $78.97
52 Week Range: $77.92 - $120.37
Oustanding Shares: 1,319,658,489
Market Cap: 104,582,935,253
6-Month Chart
TheStreet Ratings Grade for GILD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 8 8 8
Moderate Buy 1 1 1 2
Hold 9 9 9 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.00 2.06 2.06 1.94
Latest Dividend: 0.47
Latest Dividend Yield: 2.37%
Dividend Ex-Date: 09/14/16
Price Earnings Ratio: 6.99
Price Earnings Comparisons:
GILD Sector Avg. S&P 500
6.99 6.70 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-4.06% -16.70% 24.28%
GROWTH 12 Mo 3 Yr CAGR
Revenue 31.10 2.40 0.49
Net Income 50.10 6.00 0.90
EPS 62.00 6.20 0.92
Earnings for GILD:
EBITDA 23.29B
Revenue 32.64B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $2.76 $2.73 $11.47 $11.20
Number of Analysts 8 6 10 6
High Estimate $2.91 $2.98 $12.01 $11.87
Low Estimate $2.57 $2.49 $10.92 $10.57
Prior Year $3.19 $3.27 $12.45 $11.47
Growth Rate (Year over Year) -13.36% -16.51% -7.85% -2.35%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands

My Takeaways and Observations Real Money Pro($)

The U.S. dollar flat-lined. The price of crude oil increased by $2 a barrel to $46.67 on the OPEC chatter, previously mentioned. Gold fell by $4.60 to $1,325 ... not trading well. Agricultural commodities mostly lower: wheat was down $0.02, corn down $0.02, soybeans down $0.07 and oats down $0.01. Lumber up $1. Bonds were unchanged, with little movement in yields. The 10-year yield was up 1, and the long bond was flat. 2s/10s (yield curve) flat at 81 basis points. Municipals flat, but junk bond prices ripped after OPEC and closed much higher on the day. Blackstone/GSO Strategic Credit Fund (BGB) rose $0.13 to nearly $15. I would sell this strength. Banks rallied despite the lousy publicity: Congressional uproar and California state's temporary cancellation of its business relationship with Wells Fargo. More in my opening missive. The canary in the coal mine, DB, rallied after weeks of weakness. My view? Neidermeyer, dead. Deutsch Bank (DB) dead.  REITs fell small, after broad gains in the last few days. I added to my iShares Dow Jones US Real Estate ETF (IYR) short. Insurance and brokerages rallied -- albeit modestly. Staying long HIG and short Morgan Stanley (MS) , Goldman Sachs (GS) , Metlife (MET) and Lincoln National (LNC) . Biotech under-performed. Allergan (AGN) , Gilead Sciences (
Bearish
Sep 27, 2016 | 7:18 AM EDT
GILD was downgraded to Market Perform, Leerink Partners said. $94 price target. Hepatitis C market is eroding faster than expected.
Apart from the Fed, there are other factors that make investors nervous.
Emulate Graham and Buffett with Greenblatt’s 'Magic Formula' screen.
The once-mighty biotech has fallen, but entry opportunities will surface.
It's been a nasty decline, but if we rally, these three have best charts.
If and when interest rates go up, this basket of stocks should continue to do well.
Update
Sep 07, 2016 | 7:16 AM EDT
Thomson ONE Citi Biotech Conference (Day 1 of 2) - 09/07/16 - 09/08/16 Boston, MA
Bullish
Sep 06, 2016 | 7:01 AM EDT
GILD was upgraded to Buy, Jefferies said. $91 price target. Valuation call, as the stock is trading at less than 7x earnings.
Bearish
Aug 31, 2016 | 6:59 AM EDT
Shares of GILD now seen reaching $91, according to Jefferies. Estimates also reduced, given lower expected Harvoni sales. Hold rating.

Columnist Conversations

Not pretty, but former net/net (and current double-net) up 15% yesterday on 2 1/2 times normal average volume ...
PepsiCo (PEP) reported a strong beat for Q3. Earnings were $1.40 which was 8 cents ahead of the estimates. Rev...
Join me after the close for a complimentary webinar as we'll talk about the recent market action and I'll take...
No big surprise here;  company never put up a profitable quarter from operations. Says it filed in order ...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.